Terms: = Kidney tumors AND ASXL1, ENSG00000171456, 171023, Q8IXJ9, MGC71111, MGC117280, KIAA0978
12 results:
1. Cancer predisposition signaling in Beckwith-Wiedemann Syndrome drives Wilms tumor development.
Nirgude S; Naveh NSS; Kavari SL; Traxler EM; Kalish JM
Br J Cancer; 2024 Mar; 130(4):638-650. PubMed ID: 38142265
[TBL] [Abstract] [Full Text] [Related]
2. Genetic Profiling Uncovers Genome-Wide Loss of Heterozygosity and Provides Insight into Mechanisms of Sarcomatoid Transformation in Chromophobe Renal Cell Carcinoma.
Collins K; Acosta AM; Siegmund SE; Cheng L; Hirsch MS; Idrees MT
Mod Pathol; 2024 Feb; 37(2):100396. PubMed ID: 38043790
[TBL] [Abstract] [Full Text] [Related]
3. Multiomics of Bohring-Opitz syndrome truncating asxl1 mutations identify canonical and noncanonical Wnt signaling dysregulation.
Lin I; Wei A; Awamleh Z; Singh M; Ning A; Herrera A; ; Russell BE; Weksberg R; Arboleda VA
JCI Insight; 2023 May; 8(10):. PubMed ID: 37053013
[TBL] [Abstract] [Full Text] [Related]
4. Clinical findings in 39 individuals with Bohring-Opitz syndrome from a global patient-driven registry with implications for tumor surveillance and recurrence risk.
Russell BE; Kianmahd RR; Munster C; Yu A; Ahad L; Tan WH
Am J Med Genet A; 2023 Apr; 191(4):1050-1058. PubMed ID: 36751885
[TBL] [Abstract] [Full Text] [Related]
5. Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Bui TO; Dao VT; Nguyen VT; Feugeas JP; Pamoukdjian F; Bousquet G
Eur Urol; 2022 Apr; 81(4):349-361. PubMed ID: 34991918
[TBL] [Abstract] [Full Text] [Related]
6. Differences in genomic profile of high-grade urothelial carcinoma according to tumor location.
Park CK; Cho NH
Urol Oncol; 2022 Mar; 40(3):109.e1-109.e9. PubMed ID: 34663543
[TBL] [Abstract] [Full Text] [Related]
7. Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease.
Dawoud AAZ; Gilbert RD; Tapper WJ; Cross NCP
Leukemia; 2022 Feb; 36(2):507-515. PubMed ID: 34413458
[TBL] [Abstract] [Full Text] [Related]
8. Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent.
Yang ES; Nassar AH; Adib E; Jegede OA; Alaiwi SA; Manna DLD; Braun DA; Zarei M; Du H; Pal SK; Naik G; Sonpavde GP
Mol Cancer Ther; 2021 Aug; 20(8):1454-1461. PubMed ID: 34108261
[TBL] [Abstract] [Full Text] [Related]
9. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
10. Comprehensive Analysis of Somatic Mutations in Colorectal Cancer With Peritoneal Metastasis.
Lee JH; Ahn BK; Baik SS; Lee KH
In Vivo; 2019; 33(2):447-452. PubMed ID: 30804124
[TBL] [Abstract] [Full Text] [Related]
11. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
Gadd S; Huff V; Walz AL; Ooms AHAG; Armstrong AE; Gerhard DS; Smith MA; Auvil JMG; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Hermida LC; Davidsen T; Gesuwan P; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Dome JS; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Ross N; Gastier-Foster JM; Arold ST; Perlman EJ
Nat Genet; 2017 Oct; 49(10):1487-1494. PubMed ID: 28825729
[TBL] [Abstract] [Full Text] [Related]
12. Clinical management of patients with asxl1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance.
Russell B; Johnston JJ; Biesecker LG; Kramer N; Pickart A; Rhead W; Tan WH; Brownstein CA; Kate Clarkson L; Dobson A; Rosenberg AZ; Vergano SA; Helm BM; Harrison RE; Graham JM
Am J Med Genet A; 2015 Sep; 167A(9):2122-31. PubMed ID: 25921057
[TBL] [Abstract] [Full Text] [Related]
